Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Latest features in GaBI Journal, 2019, Issue 3 / Professor Philip D Walson, MD


Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective / Brian Godman, BSc, PhD; Eleonora Allocati, BSc, MSc; Evelien Moorkens, BSc, MSc

Original Research

Pharmacy Chain Drives Choice among Manufacturers of Generic Drugs in the US Medicare Population / Steven Kozlowski, MD, Ellen Tworkoski, MS, MPhil, Carmen Dekmezian, MS, Yanchang Zhang, MPH, Natasha Flowers, BA, Alvin So, MS, Andreas M Schick, PhD, Michael Wernecke, BA, Thomas MaCurdy, PhD, and Jeffrey A Kelman, MD, MMSc

Review Article

An Ever-Evolving Landscape: an Update on the Rapidly Changing Regulatory and Reimbursement of Biosimilars in Canada / Eric C K Siu, MSc, PhD; Anne Tomalin, BA, BSc; Kevin West, BA; Sandra Anderson, BA, MBA; George Wyatt, BSc, MBA

The Evolution of the European Biosimilars Market / Michael S Reilly, Esq; Professor Philip J Schneider, MS, FASHP


It is time to change US trade policy to foster access to medicines / Maria Fabiana Jorge, MBA


An evolving role for non-governmental organizations dealing with registration backlogs and rising costs: the example of cancer biosimilars in South Africa / Paul Malherbe, PhD


Why ‘similar’ can make a big difference / Zorana Maravic, BSc, MBA

Meeting Report

1st ASEAN Overview Workshop on GMP for Biologicals/Biosimilars 2018 – Report / Elwyn Griffiths, PhD, DSc, Professor Chong Hock Sia

Special Report

A progress report on the 3rd International Symposium on Scientific and Regulatory Advances in Biological and Non-Biological Complex Drugs: A to Z in Bioequivalence / Jon SB de Vlieger, Daan JA Crommelin, Beat Flühmann, Imre Klebovich, Stefan Mühlebach, Vinod P Shah

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Last update: 2019-11-25 Go Back Print

Comments are closed.